semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy Idiopathic Pulmonary Fibrosis Other Interstitial Lung Disease Without Curative Therapy Congestive Heart Failure NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year Malignancy Any Stage 3B or 4 Solid Tumor Age > 18 years Chronic Obstructive Pulmonary Disease (COPD) with severe or very severe airflow obstruction on pulmonary function testing and or receiving or eligible to receive long-term oxygen therapy AND/OR Idiopathic Pulmonary Fibrosis (IPF) AND/OR Other interstitial lung disease without curative therapy AND/OR Any stage 3B or 4 solid tumor AND/OR Congestive Heart Failure (CHF) either New York Heart Association NYHA) class IV or NYHA class III plus 1 hospitalization in the past year No previously signed advance directive in the medical record Neither listed for nor considering lung or heart transplantation High anticipated risk for critical illness in the next 2 years based on clinical judgment Interest in thinking about filling out an Advance Directive  Diseases for which life-extending medical therapies may be available Inability to speak and/or read English proficiently New clinic patients meeting the clinic provider for the first time Patients being actively evaluated or already listed for transplants Patients already having an AD Cognitive impairment necessitating proxy consent
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease COPD diagnosis with exacerbation No contraindication of physiotherapy Signed written consent Medical approval for inclusion  Heart disease Neurological patients Contraindications of physiotherapy
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 21.0-90.0,  Chronic Obstructive Pulmonary Disease patients with COPD meeting the Global Initiative for Obstructive Lung Disease (GOLD) guidelines, with forced expiratory volume in the first second of expiration (FEV1) <80% predicted, FEV1/FVC ratio <70% predicted (FVC= forced vital capacity), and total lung capacity (TLC) >80% predicted), with or without sputum, will be included. The severity of COPD will be classified according to GOLD Stage I: mild FEV1/FVC<0.70 and FEV1>80% predicted; Stage II: moderate FEV1/FVC<0.70 and 50<FEV1<80% predicted; Stage III: severe FEV1/FVC<0.70 and 30<FEV1<50% predicted; Stage IV: very severe FEV1/FVC<0.70 and FEV1<30% or FEV1<50% predicted plus chronic respiratory failure  Patients with Upper respiratory tract infection within the previous 28 days Treatment with antibiotics within 4 weeks prior the study Acute dyspnoea or hemoptysis Chest pain or recent history of rib fracture or pneumothorax Acute cardiovascular events in the previous 3 months Any history or evidence of renal, gastrointestinal or hepatic disease Any history and evidence of neuropsychiatric disease Alcohol, drug abuse or any other condition associated with poor compliance Breast feeding
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Men and women aged 40 years or over History of current or former smoking of at least 10 pack-years Cooperative outpatients, with a COPD diagnosis established by the measurement of FEV1/FVC < 0.7 post-bronchodilation in basal spirometry (without use of medication or post-washout). Moderate to severe stage patients will be included, with post-bronchodilator FEV1 between 30 and 80% of the normal value according to GOLD 2011 since the in this trial will be based on spirometry results Pregnant women or nursing mothers History of asthma at visit 1 indicated by, but not limited to Onset of respiratory symptoms suggestive of asthma (such as coughing, wheezing, shortness of breath) before the age of 40 History of diagnosed asthma History of respiratory tract infection within six weeks prior to Visit 1 History of hospitalization or emergency care for a COPD exacerbation in the 3 months prior to Visit 1 Subjects who require use of home oxygen therapy
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Fever COPD Obesity Congenital Heart Disease Respiratory Distress Adults with controlled and non-controlled hypertension (hypertension defined as > 130/90 on two separate occasions and history of hypertension) Adults with known chronic obstructive pulmonary disease in respiratory distress with oxygen saturations < 90% Febrile adults (temp at triage > 38 C) with no significant co-morbidities Elderly (>70 years) patients with no significant co-morbidities Obese adults (BMI > 30) Febrile (temp at triage > 38 C) and non-febrile children (age < 18 yrs) Obese children (BMI > 30) Neonates (age < 6 weeks) Children with corrected cyanotic congenital heart disease Children in respiratory distress that present with oxygen saturations < 90%  -Subjects with unstable vital signs will be excluded
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 35.0-75.0,  Pulmonary Emphysema HRCT-confirmed diagnosis of lung emphysema by two independent radiologists post-bronchodilator FEV1/FVC ratio < 0.7 post-bronchodilator FEV1 % predicted value ≥ 20% and < 50% age 35 and 75 years of, of either sex, and of any race current or ex-smoker, with a cigarette smoking history ≥ 10 pack-years  • asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, or lung cancer) α1-Antitrypsin deficiency Presence of bullae (more than 10 cm in the diameter) active infection within 4 weeks of screening significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening clinically relevant uncontrolled medical condition not associated with COPD documented history of uncontrolled heart failure pulmonary hypertension due to left heart condition Subject has evidence of active malignancy, or prior history of active malignancy Subject has a life expectancy of < 6 months
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Snoring every night snoring; 2. no medication known to influence nasal resistance (e.g., antihistamines, vasoconstrictors, topical or systemic steroids); 3. no smoking for the last 6 months; 4. no upper or lower respiratory tract disease (e.g., upper respiratory tract infection, rhinitis, sinusitis, chronic obstructive pulmonary disease), including a history of nasal allergy; and 5. written informed consent from each patient  duration of snoring less than 60 minutes during sleep study, and 2. central apnoeas more than five percent of total apnoeas
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Dyspnea Male or Female Aged ≥40 years Ambulatory Cigarette smoking history ≥15 pack years No change in medication dosage or frequency of administration, with no exacerbations or hospitalization in the preceding 6 weeks Post-bronchodilator Forced Expiratory Volume in 1 second between 30-80% predicted Post-bronchodilator Forced Expiratory Volume in 1 second/forced vital capacity ratio of <70%  Presence of active cardiopulmonary disease other than COPD Use of domiciliary oxygen Exercise-induced arterial blood oxyhemoglobin desaturation to <80% on room air Body Mass Index <18.5 or ≥35 kg/m2 Allergy to latex Allergy to lidocaine or its "caine" derivates
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-90.0,  Chronic Obstructive Pulmonary Disease (COPD) Signature of informed consent COPD patients with age raging from 50 to 85 years old Patients with at least a history of COPD of one year COPD patients clinically stable in the last three months COPD subjects with FEV1 (Forced Expiratory Volume in 1st second)<70% of predicted value FEV1/FVC (Forced Expiratory Volume in 1st second/Forced Vital Capacity) <88% (males) or <89% (females) of LLN (Low Levels of Normality) COPD former or active smokers with at least a smoking history of 20 pack year  Acute Bronchial Exacerbation at recruitment Fertile women with age between 18 and 50 years old or with active period Pregnancy Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment FEV1/FVC more than 70% of predicted value in basal conditions FEV1 more than 70% of predicted value in basal conditions Known deficit of alpha 1 antitrypsin Subjects that underwent a Lung Volume Reduction Surgery (LVRS) Subjects with known positivity to Human Immunodeficiency Virus (HIV) Misuse of alcool or drugs
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation patients > 40 years old Acute exacerbation of COPD  Medico social conditions not allowing home discharge Other causes of Dyspnea: Pneumothorax, pulmonary embolism, pulmonary oedema, lung cancer Pneumonia on chest ray acute respiratory distress requiring immediate ICU transfer
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Chronic Obstructive Pulmonary Disease Patients with moderate or severe COPD exacerbation who are older than 40-years-old A smoking history of at least 10-pack-years Requiring hospitalization because of COPD exacerbation  Presence of asthma, allergic rhinitis, atopy or any systemic disease (such as diabetes mellitus or hypertension) Exposed to systemic corticosteroids in the preceding month or used more than 1,500 microg/d of inhaled beclomethasone equivalent Admission to the intensive care unit (pH<7.30 and/or PaCO2 > 70 mm Hg, and/or PaO2 < 50 mm Hg despite supplemental oxygen) If a specific cause for the exacerbation, such as pneumonia, pneumothorax, or heart failure, was diagnosed
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Informed consent Subject must give their signed and dated written informed consent to participate Subject understands and is willing, able, and likely to comply with study procedures and restrictions Subject must be able to read, comprehend, and record information in English Age: >=40 years of age at Visit 1 Gender: Male or female subjects COPD diagnosis subjects with a clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society Severity of disease Subject with a measured post-albuterol Forced expiratory volume in 1 second (FEV1)/ Forced vital capacity (FVC) ratio of <=0.70 at Visit 1 Subjects with a measured post-albuterol FEV1 <=70% of predicted normal values calculated using Third National Health and Nutrition Examination Survey reference equations at Visit 1  Previous experience with the inhaler Subjects who used any inhaler (e.g., participated in a clinical study of fluticasone propionate/salmeterol, or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1 Previous experience with the inhaler Subjects who used any inhaler (e.g., participated in a clinical study of FF/VI or GSK573719/GW642444 [umeclidinium/vilanterol], or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1 Asthma: Subjects with a current diagnosis of asthma Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD Poorly controlled COPD: Subjects with symptoms of poorly controlled COPD such as Acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician, in the 4 weeks prior to Visit 1 Hospitalization due to acute worsening of COPD within 4 weeks of Visit 1 Use of a total of 8 puffs/day or more of short-acting symptom relief medications such as albuterol and ipratropium for 2 consecutive days or any 3 days within 7 days immediately preceding Visit 1
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  COPD volunteers with COPD for Patients Group volunteers without any respiratory disease for the control group  individuals with history of tuberculosis or other lung disease heart disease in general and disability in the exams
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.083-19.0,  Sepsis Critical Illness Children age 1 month-19 years 2. Diagnosis of severe sepsis diagnosed as clinical sepsis syndrome (requires two of the following criteria) Source of infection Fever or Hypothermia Leukocytosis or Leucopenia Poor organ perfusion (such as delayed capillary refill or decreased urine output or hypotension) Bacteremic sepsis demonstrated by positive blood culture 3. Weight greater or equal to 4.0 kg 4. Need for enteral nutrition by a nasogastric/nasoduodenal tube 5. Presence of central and/or arterial venous access as per clinical indication  Patients with metabolic diseases (i.e. Insulin dependent diabetes mellitus, urea cycle disorders, cystinuria, etc.) 2. Pregnancy 3. Primary liver failure 4. Primary renal failure 5. Patients unable to tolerate enteral feedings 6. Weight less than 4.0 kg